SDS-PAGE Analysis Purified CD79a Recombinant Mouse Monoclonal Antibody (rIGA/6986). Confirmation of Purity and Integrity of Antibody.
Western blot analysis of Daudi cell lysate using CD79a Recombinant Mouse Monoclonal Antibody (rIGA/6986).
Formalin-fixed, paraffin-embedded human tonsil stained with CD79a Recombinant Mouse Monoclonal Antibody (rIGA/6986). Inset: PBS instead of primary antibody; secondary only negative control.
Formalin-fixed, paraffin-embedded human tonsil stained with CD79a Recombinant Mouse Monoclonal Antibody (rIGA/6986). HIER: Tris/EDTA, pH9.0, 45min. 2: HRP-polymer, 30min. DAB, 5min.
Known Applications & Suggested Dilutions
Host / Ig Isotype
Mol. Weight of Antigen
Specificity & Comments
A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.